🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Macular Degeneration, Dry

Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited Retinal Disease (DEFINE-IRD) NCT07502664n/a1 site📍 Irvine Ray Therapeutics, Inc. AVIGA3 (Cohort 2.0) NCT07255859NA1 site📍 Singapore Tan Tock Seng Hospital · Tests: Amsler Grid, AVIGA Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration NCT04339764Phase 1, Phase 22 sites📍 Baltimore📍 Bethesda National Eye Institute (NEI) · Tests: iPSC-derived RPE/PLGA transplantation A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio NCT07215390Phase 278 sites📍 Gilbert📍 Mesa📍 Phoenix Apellis Pharmaceuticals, Inc. · Tests: APL-3007, pegcetacoplan (APL-2), APL-3007, pegcetacoplan (APL-2), Placebo, Syfovre Retinal Photoreceptor Outer Segment Length Before and After Light Stimulation - a Pilot Study NCT03921931NA1 site📍 Vienna Medical University of Vienna · Tests: White light stimulation Project AMD: Comprehensive Characterisation of Age-Related Macular Degeneration and Its Progression NCT04739319n/a1 site📍 East Melbourne Center for Eye Research Australia · Tests: N/A Observational study (CIRRUS-2023-1) CLINICAL CLIN Assessment of PathFinder 1.0 on the CIRRUS 6000 and the CIRRUS 5000 NCT07680244NA6 sites📍 Tucson📍 Mountain View📍 San Francisco Carl Zeiss Meditec-Dublin CoCe · Tests: PathFinder 1.0 on CIRRUS HD-OCT Phase 3 Study to Assess Efficacy, Safety & Tolerability of OCU410 For Geographic Atrophy Secondary to Dry AMD NCT07770828Phase 33 sites📍 Phoenix📍 Erie📍 McAllen Ocugen · Tests: OCU410 A Study in Adults With Geographic Atrophy NCT07606365Phase 256 sites📍 Bakersfield📍 Beverly Hills📍 Aurora Sitala Bio LTD · Tests: STL303, Placebo A Study to Assess the Efficacy and Safety of RO7965032 in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration NCT07851259Phase 25 sites📍 Walnut Creek📍 Winston-Salem📍 Erie Genentech, Inc. · Tests: RO7965032, Placebo Long-Term Analysis of DImethyl Fumarate, to Slow the Growth of Areas of Geographic Atrophy NCT04292080Phase 21 site📍 Créteil Assistance Publique - Hôpitaux de Paris · Tests: Dimethyl Fumarate (TECFIDERA™), No active : no treatment Safety and Clinical Applicability of Transcorneal Electrical Stimulation (TES) in Geographic Atrophy NCT07531927NA5 sites📍 Hamburg📍 München📍 Stuttgart Okuvision GmbH · Tests: Transcorneal electrical stimulation (TES) with the OkuStim 2 System, Transcorneal electrical stimulation (TES) with the… An Optimised GA Interventional Trial (Opti-GAIN) to Test if Treatment With CTx001 is Safe and Works for People With Geographic Atrophy (GA) NCT07392255Phase 1, Phase 28 sites📍 Carmel📍 Reno📍 Dallas Complement Therapeutics · Tests: CTx001 Phase 1 Study of C.001 in Retinal Degeneration NCT07594236Phase 13 sites📍 Beverly Hills📍 Palo Alto📍 Sacramento Cellio Therapeutics Inc · Tests: Injection Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD NCT06659445Phase 2120 sites📍 Gilbert📍 Phoenix📍 Bakersfield ONL Therapeutics · Tests: ONL1204 Opthalmic solution, Avacincaptad Pegol intravitreal solution, Sham Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration NCT06662162NA13 sites📍 Poway📍 Manchester📍 Lemont i-Lumen Scientific AUS PTY LTD · Tests: i-Lumen AMD Survival of Monocytes Collected From Patients With Atrophic AMD in Retinal Pigmented Epithelium Explants NCT04697095NA2 sites📍 Lyon📍 Lyon Hospices Civils de Lyon · Tests: Blood samples High Resolution, High-speed Multimodal Ophthalmic Imaging NCT04129021NA1 site📍 Paris Centre Hospitalier National d'Ophtalmologie des Quinze-Ving… · Tests: High-resolution retinal imaging through adaptive optics, High-resolution retinal imaging through holographic systems A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration NCT03178149Phase 120 sites📍 Phoenix📍 Los Angeles📍 Palo Alto Astellas Institute for Regenerative Medicine · Tests: ASP7317, tacrolimus, trimethoprim-sulfamethoxazole, Acyclovir, Nystatin Safety and Tolerability of RPE Stem Cell-derived RPE(RPESC-RPE) Transplantation in Patients With Dry Age-related Macular Degeneration (AMD) NCT04627428Phase 1, Phase 23 sites📍 Beverly Hills📍 Palo Alto📍 Ann Arbor Luxa Biotechnology, LLC · Tests: RPESC-RPE-4W Phase 2 Study of ADX-038 in Participants With Geographic Atrophy NCT06990269Phase 283 sites📍 Gilbert📍 Phoenix📍 Bakersfield ADARx Pharmaceuticals, Inc. · Tests: ADX-038, Placebo A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration NCT07441642Phase 259 sites📍 Huntington Beach📍 Sacramento📍 Santa Barbara Novartis Pharmaceuticals · Tests: FWY003, Placebo Lesion-tailored, Fundus-controlled Perimetry in Geographic Atrophy (GA). NCT07582042n/a1 site📍 Salt Lake City University of Utah Stem Cell Ophthalmology Treatment Study II NCT03011541NA4 sites📍 Westport📍 Coral Springs📍 Vienna MD Stem Cells · Tests: Arm 1 Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration NCT06375239n/a1 site📍 Irvine Ray Therapeutics, Inc. Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult Participants NCT07230834Phase 19 sites📍 Lakewood📍 East Weymouth📍 Austin Regeneron Pharmaceuticals · Tests: Pozelimab A Study to Evaluate the Safety and Effect of TO-O-1007 Intravitreal Implant in Subjects With Geographic Atrophy NCT07668804Phase 1, Phase 23 sites📍 Hurstville📍 Sydney📍 Launceston Theratocular Biotek Co. · Tests: TO-O-1007 (low-dose), TO-O-1007 (high-dose), Sham injection Multicenter Clinical Study of the SING-IMT in Patients with Late-stage AMD NCT05438732NA10 sites📍 Loma Linda📍 Long Beach📍 Sarasota VisionCare, Inc. · Tests: smaller incision, new generation implantable miniature telescope (SING-IMT) A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) NCT06635148Phase 2, Phase 3104 sites📍 Tucson📍 Fullerton📍 La Jolla Janssen Research & Development, LLC · Tests: JNJ-81201887, Sham Procedure A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration NCT07215234Phase 1, Phase 235 sites📍 Peoria📍 Scottsdale📍 Beverly Hills Sanofi · Tests: SAR446597, Sham Comparator
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy